-
-
-
-
-
-
-
Enliven Therapeutics stock surges 28% on Merck-Terns deal
-
-
-
-
-
-
-
Enliven Therapeutics, Inc (ELVN) Tops Q2 EPS by 6c
-
-
-
-
-
-
-
Enliven Therapeutics (ELVN) PT Raised to $41 at Mizuho
-
-
-
-
-
-
-
Clear Street Starts Enliven Therapeutics (ELVN) at Buy, Top Pick
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN)
-
-
-
-
413,572 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

